Unlock stock picks and a broker-level newsfeed that powers Wall Street.
BSE - Delayed Quote INR

Ajanta Pharma Limited (AJANTPHARM.BO)

Compare
2,490.75
-130.90
(-4.99%)
At close: 3:29:30 PM GMT+5:30
Loading Chart for AJANTPHARM.BO
  • Previous Close 2,621.65
  • Open 2,615.00
  • Bid 2,480.05 x --
  • Ask 2,492.80 x --
  • Day's Range 2,475.00 - 2,639.20
  • 52 Week Range 2,049.75 - 3,485.75
  • Volume 5,945
  • Avg. Volume 4,754
  • Market Cap (intraday) 311.125B
  • Beta (5Y Monthly) 0.25
  • PE Ratio (TTM) 34.80
  • EPS (TTM) 71.57
  • Earnings Date Apr 30, 2025 - May 5, 2025
  • Forward Dividend & Yield 54.00 (2.06%)
  • Ex-Dividend Date Nov 6, 2024
  • 1y Target Est 3,031.73

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

www.ajantapharma.com

8,073

Full Time Employees

March 31

Fiscal Year Ends

Recent News: AJANTPHARM.BO

View More

Performance Overview: AJANTPHARM.BO

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

AJANTPHARM.BO
15.04%
S&P BSE SENSEX (^BSESN)
3.55%

1-Year Return

AJANTPHARM.BO
14.89%
S&P BSE SENSEX (^BSESN)
1.53%

3-Year Return

AJANTPHARM.BO
119.07%
S&P BSE SENSEX (^BSESN)
24.34%

5-Year Return

AJANTPHARM.BO
201.61%
S&P BSE SENSEX (^BSESN)
173.15%

Compare To: AJANTPHARM.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AJANTPHARM.BO

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    327.48B

  • Enterprise Value

    320.23B

  • Trailing P/E

    36.63

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.33

  • Price/Book (mrq)

    8.91

  • Enterprise Value/Revenue

    7.14

  • Enterprise Value/EBITDA

    23.68

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19.81%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    45.32B

  • Net Income Avi to Common (ttm)

    8.98B

  • Diluted EPS (ttm)

    71.57

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.42B

  • Total Debt/Equity (mrq)

    0.89%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: AJANTPHARM.BO

View More

Company Insights: AJANTPHARM.BO

Research Reports: AJANTPHARM.BO

View More

People Also Watch